casno. : CAS 96829-58-2
Orlistat is a obesity treatment drug that does not act on the central nervous system. It only acts on the gastrointestinal tract, prevents triacylglycerol from being hydrolyzed into free fatty acids and monoacylglycerol esters by inhibiting the lipase in the gastrointestinal tract, reduces the absorption of fat (triacylglycerol) in the diet by the intestinal mucosa, and promotes the elimination of fat. Lipase is an enzyme necessary for the gastrointestinal tract to decompose fat. This product can combine with the serine residues of gastric and pancreatic lipases to inactivate the lipase, so that it can not decompose the fat in food into free fatty acids and inhibit the utilization and absorption of fat. In addition, this product can also reduce the risk factors related to obesity.